Novo Nordisk and OpenAI Form Strategic Partnership to Transform Drug Discovery and Distribution

JAKARTA - Novo Nordisk today announced a strategic partnership with OpenAI. This collaboration puts Novo Nordisk at the forefront of AI transformation in the health sector while accelerating the company's efforts to bring more innovative and quality treatment options to patients.

This partnership will leverage advanced AI capabilities to analyze complex data, identify promising drug discoveries, and accelerate the time from research stage to when the drug can be accessed by patients. This collaboration is designed with strict data protection, governance, and human oversight to ensure ethical and regulatory compliant use of the technology.

"This partnership is an important step in affirming Novo Nordisk's position as a leader in the new era of healthcare. Millions of people living with obesity and diabetes need more treatment options, and we realize that there are still many therapies that have not been discovered that can change their lives," said Mike Doustdar, President and CEO of Novo Nordisk, in a statement. , Thursday, April 16.

"Integrating AI into everyday work allows us to analyze data on a scale that was previously impossible, identify patterns that have never been seen before, and test hypotheses faster than ever before. Thus, this collaboration helps us accelerate the discovery of new therapies and bring them to market faster than ever," he added.

OpenAI will help Novo Nordisk improve the company's global workforce skills and AI literacy across the organization. This partnership will also leverage OpenAI's capabilities to optimize efficiency in manufacturing, supply chain, distribution, and overall corporate operations. Pilot programs will be launched across departments, including research and development, manufacturing, and commercial operations, with full integration targeted for completion by the end of 2026.

"AI is transforming various industries, and in the field of life sciences, this technology can help humans live better and longer," said Sam Altman, CEO of OpenAI.

"This collaboration with Novo Nordisk will help accelerate scientific discovery, run smarter global operations, and redefine the future of patient care," he explained.

This step continues Novo Nordisk's previous AI initiatives, including collaborations with various technology partners and research organizations to build best-in-class capabilities.